TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04527224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AstroStem-V
Description: Allogenic adipose tissue-derived mesenchymal stem cells (AdMSCs)
Study: NCT05215392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Connections program
Description: Family members in the experimental group of this study will receive an ecological momentary intervention (EMI) derived from an ecological momentary assessment (EMA) via the Family Connections smartphone app. Family members in this condition will receive the manual of Family Connections which contains all the information on the program sessions conducted and the skills training strategies in writing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Connections program
Description: Family members in the experimental group of this study will receive an ecological momentary intervention (EMI) derived from an ecological momentary assessment (EMA) via the Family Connections smartphone app. Family members in this condition will receive the manual of Family Connections which contains all the information on the program sessions conducted and the skills training strategies in writing.
Study: NCT05045612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stop antibiotic therapy
Description: Stop antibiotic therapy instituted by the admitting physician
Study: NCT06464913

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: With or without chest wall RT
Description: Supraclavicular and infraclavicular lymphatic drainage area radiotherapy with or without chest wall RT
Study: NCT06033209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N332-GT5 gp140 (IM, Bolus)
Description: IM in the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N332-GT5 gp140 (IM, Bolus)
Description: IM in the deltoid
Study: NCT05264831

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Vein Isolation (PVI) alone
Description: PVI procedures correspond to point-by-point 50W AI-guided RF applications (400 posterior LA wall, and 550 elsewhere). The PVI will be validated by the absence of any activity recorded inside the PV encirclement by a multipolar catheter (either a Lasso catheter or a Pentaray catheter) (entrance block) and by the non-capture of the LA despite pacing maneuvers from inside the encirclement (exit block). The bidirectional block will be validated again after a 15-minutes waiting period.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PVI procedure associated with substrate modulation
Description: PVI procedure associated with substrate modulation
Study: NCT05868577

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Local anesthetic (LA) with Saline injection
Description: The PI will then administer the injection using an infracalcaneal needle peppering
Study: NCT05499650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Regiment
Description: Subjects will undergo supervised aerobic exercise. There will be a set goal mean energy expenditure of at least 1000 kcal/wk after a two-week ramp-up period. The protocol will include 30 minutes of moderate-intensity exercise with a treadmill and cycle ergometry, two times weekly. Strenuous resistance training and swimming will be withheld from this protocol due to the potential concerns for safety in exacerbating dissections. Heart rate and ratings of perceived exertion will be quantified during the therapy with a standard set heart rate ad pulse pressure threshold for discontinuing exercise protocols.
Study: NCT06483932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dried barberry
Description: Subjects will ingest 10 grams of powdered seedless barberry on a daily basis, in conjunction with the low-calorie diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-calorie diet
Description: Diet with 500 kcal subtracted from the daily energy requirement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-calorie diet
Description: Diet with 500 kcal subtracted from the daily energy requirement
Study: NCT04910256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huatuo Zaizao Pills
Description: Patients take 8g of HuaTuo Zaizao pill three times a day. Treatment lasts for 12 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Basic treatment
Description: It accordance with the Guidelines for diagnosis and treatment of ischemic stroke in China,and the drug and dosage will be formulated by the researchers according to the clinical situation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic treatment
Description: It accordance with the Guidelines for diagnosis and treatment of ischemic stroke in China,and the drug and dosage will be formulated by the researchers according to the clinical situation.
Study: NCT06518564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Human IgG1 antibody, 20mL single-use vials, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1774
Description: Ataxia Telangiectasia and Rad3-related protein (ATR) inhibitor, 30 and 50 mg capsules, taken orally per protocol.
Study: NCT06287918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3HP-2827
Description: 3HP-2827 will be administered orally once daily in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3HP-2827
Description: 3HP-2827 will be administered orally once daily in 28-day cycles.
Study: NCT05189457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteinizing Hormone Releasing Hormone
Description: During the first strike, LHRH will be administered for 12 to 18 weeks. During the second strike, participants will receive 4 cycles of LHRH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New Hormonal Agent
Description: During the first strike, if Abiraterone is chosen 1000mg of Abiraterone will be taken orally. If Enzalutamide is used, 160 mg will be taken orally every 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: During the second strike, participants will receive 4 cycles of Docetaxel at 75mg/m2 given intravenously at day 1 of ever 21 days. For participants with positive prostate biopsy or detectable PSA, the second strike will receive 2 additional cycles of docetaxel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: During the second strike, participants will receive 6 doses of Tislelizumab at 200 mg, given intravenously once every 3 weeks.
Study: NCT05055635

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pencil beam proton therapy
Description: Neo-adjuvant or definitive pencil beam proton therapy: 55 Gy(RBE)/44fx - 65 Gy(RBE)/52 fx (1.25 Gy per fraction), two fractions a day
Study: NCT04335799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program Intensive Lifestyle Intervention plus stress management training
Description: 12-month evidence based weight loss intervention with additional training on stress management strategies

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Prevention Program Intensive Lifestyle Intervention plus general women's health topics
Description: 12-month evidence based weight loss intervention with an attention control of general women's health topics
Study: NCT05419492

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: ETX101
Description: ETX101 is a non-replicating, recombinant adeno-associated viral vector serotype 9 (rAAV9) comprising a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A). ETX101 is intended as a one-time intracerebroventricular (ICV) administration.
Study: NCT05793892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine tetracaine cream
Description: The test drug and the control drug will be uniformly spread over the treatment area using a tongue platula to form a thin layer of approximately 1 mm,right then left . The drug remained in the treatment area for 30 minutes (± 2 minutes) .
Study: NCT05030766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: 6 weeks of Nicotine replacement patches

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: 6 weeks of Nicotine replacement patches

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: 6 weeks of Nicotine replacement patches
Study: NCT06397872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg Resmetirom Tablet
Description: Once daily oral dose for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg Resmetirom Tablet
Description: Once daily oral dose for 6 days
Study: NCT05030766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: 6 weeks of Nicotine replacement patches

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training Smoking Cessation Intervention
Description: Mindfulness Training Smoking Cessation Intervention administered online via Zoom. Each session lasts 60-90 minutes, twice weekly for 4 weeks for a total of 8 sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training Smoking Cessation Intervention
Description: Mindfulness Training Smoking Cessation Intervention administered online via Zoom. Each session lasts 60-90 minutes, twice weekly for 4 weeks for a total of 8 sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training Smoking Cessation Intervention
Description: Mindfulness Training Smoking Cessation Intervention administered online via Zoom. Each session lasts 60-90 minutes, twice weekly for 4 weeks for a total of 8 sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management Smoking Cessation Intervention
Description: Contingency Management Smoking Cessation Intervention includes one orientation session lasting about 60-90 minutes administered via Zoom. Participants will then be required to contact the research associate about their quitting progress three times a week for 4 weeks also by zoom.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management Smoking Cessation Intervention
Description: Contingency Management Smoking Cessation Intervention includes one orientation session lasting about 60-90 minutes administered via Zoom. Participants will then be required to contact the research associate about their quitting progress three times a week for 4 weeks also by zoom.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management Smoking Cessation Intervention
Description: Contingency Management Smoking Cessation Intervention includes one orientation session lasting about 60-90 minutes administered via Zoom. Participants will then be required to contact the research associate about their quitting progress three times a week for 4 weeks also by zoom.
Study: NCT04804020

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NC
Description: The first ultrasound scan will be performed on the second to the fourth day of the menstrual cycle to identify any problem related to the patients' uterus or adnexa. The second ultrasound will be performed on the sixth day of the cycle. Daily ultrasound and serum estradiol and LH level evaluation will be performed when the mean diameter of the dominant follicle of ≥14 mm. LH surge initiation is defined as a concentration of 180% above the latest serum value available in that patient with a continued rise thereafter9 to a level of 20 IU/l or more10 detected by the ECLIA method (Roche Cobas® E 801, Roche Diagnostics, Germany). Embryo transfer will be scheduled by the time of the initiation of LH and embryo stages.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mNC
Description: The first ultrasound scan will be performed on the second to the fourth day of the menstrual cycle to identify any problem related to patients' uterus or adnexa. A second ultrasound scan will be performed on the sixth day of the cycle; if there is at least one follicle with a diameter of ≥12 mm, an ultrasound scan will be performed daily. When the dominant follicle's mean diameter is ≥16 mm, human chorionic gonadotropin (Ovitrelle® 250 μg; Merck, Kenilworth, NJ, USA) will be injected to trigger ovulation. Embryo transfer will be scheduled by the time of the hCG injection and embryo stages.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AC
Description: The endometrium is prepared using oral estradiol valerate (Valiera®; Laboratories Recalcine) 8 mg/day, ranging from the second or fourth menstruation day. The endometrial thickness will be monitored from day six onwards, and vaginal progesterone (Utrogestan®; Besins) 800 mg/day will be initiated when endometrial thickness reaches ≥7 mm. Estradiol exposure must be lasting for ≥9 days before progesterone administration. Embryo transfer will be scheduled by the time of the initiation of progesterone and embryo stages.
Study: NCT04710277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid-sparing multimodal pain management
Description: Ice pack applied to abdominal incisions for 20 minutes every 2 to 3 hours for 24 hours after surgery and scheduled acetaminophen and NSAID for 96 hours after surgery. Narcotic pain medication for severe breakthrough pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Scheduled acetaminophen and NSAID for 24 hours after surgery. Narcotic pain medication for severe breakthrough pain.
Study: NCT05976438

Intervention type: DRUG
Group type: OTHER
Intervention: Amlodipine
Description: Amlodipine 5mg and Amlodipine 10mg will be one of the study drugs the patients will receive.

Intervention type: DRUG
Group type: OTHER
Intervention: Amlodipine
Description: Amlodipine 5mg and Amlodipine 10mg will be one of the study drugs the patients will receive.

Intervention type: DRUG
Group type: OTHER
Intervention: Chlortalidone
Description: Chlortalidone 25mg will be one of the study drugs the patients will receive.

Intervention type: DRUG
Group type: OTHER
Intervention: Chlortalidone
Description: Chlortalidone 25mg will be one of the study drugs the patients will receive.
Study: NCT05386485

Intervention type: OTHER
Intervention: None intervation
Description: Observational Study

Intervention type: OTHER
Intervention: None intervation
Description: Observational Study

Intervention type: OTHER
Intervention: None intervation
Description: Observational Study

Intervention type: OTHER
Intervention: None intervation
Description: Observational Study

Intervention type: OTHER
Intervention: None intervation
Description: Observational Study
Study: NCT05558917

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PECS BLOCK 2
Description: With the patient supine, the linear probe will be placed in the sagittal plane slightly lateral to the hemiclavicular line ipsilateral to the surgical site. Once both muscle planes of interest have been identified, in-plane needle insertion will proceed in the cranio-caudal direction. The first local anesthetic administration with Ropivacaine 0.5% will be 20ml between small pectoralis and serratus anterior. Coming out with the needle, 10ml of Ropivacaine 0.5% will then be injected between large and small pectoral.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP BLOCK
Description: Positioning yourself behind the patient, lying on her side with the surgical hemilateral on top, you place the linear ultrasound probe in the sagittal plane and find the lateral margin of the transverse process. At this point, the blocking needle is inserted in the caudocranial direction and 25ml of Ropivacaine 0.5% is injected, taking care to visualize the anesthetic spread in the cranial direction.
Study: NCT05793892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine tetracaine cream
Description: The test drug and the control drug will be uniformly spread over the treatment area using a tongue platula to form a thin layer of approximately 1 mm,right then left . The drug remained in the treatment area for 30 minutes (± 2 minutes) .
Study: NCT04641403

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The surgeon performed Laparoscopic-assisted TAP (LTAP) block
Description: After the induction of anesthesia, the first port will be inserted through the umbilicus and a 12 mmHg pneumoperitoneum will establish as a standard. Under the direct view of the laparoscopic camera, the block will be performed by inserting a 22-G needle just above the iliac crest through the midclavicular line posteriorly into the triangle of Petit and then inserting the needle below the costal arch through the midclavicular line towards the anterior axillary line into the subcostal plane. The block needle will be advanced under direct view until the two pops were felt and the extraperitoneal space will reach without puncturing the parietal peritoneum, and pulling back the needle 0.5 cm, the area of the thin transversus abdominis muscle fibers wiil be infiltrated. In this area, the correct plane of the needle tip will confirm by observing Doyle's bulge and the spread of the local anesthetic.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The surgeon performed Laparoscopic-assisted TAP (LTAP) block
Description: After the induction of anesthesia, the first port will be inserted through the umbilicus and a 12 mmHg pneumoperitoneum will establish as a standard. Under the direct view of the laparoscopic camera, the block will be performed by inserting a 22-G needle just above the iliac crest through the midclavicular line posteriorly into the triangle of Petit and then inserting the needle below the costal arch through the midclavicular line towards the anterior axillary line into the subcostal plane. The block needle will be advanced under direct view until the two pops were felt and the extraperitoneal space will reach without puncturing the parietal peritoneum, and pulling back the needle 0.5 cm, the area of the thin transversus abdominis muscle fibers wiil be infiltrated. In this area, the correct plane of the needle tip will confirm by observing Doyle's bulge and the spread of the local anesthetic.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The surgeon performed Laparoscopic-assisted TAP (LTAP) block
Description: After the induction of anesthesia, the first port will be inserted through the umbilicus and a 12 mmHg pneumoperitoneum will establish as a standard. Under the direct view of the laparoscopic camera, the block will be performed by inserting a 22-G needle just above the iliac crest through the midclavicular line posteriorly into the triangle of Petit and then inserting the needle below the costal arch through the midclavicular line towards the anterior axillary line into the subcostal plane. The block needle will be advanced under direct view until the two pops were felt and the extraperitoneal space will reach without puncturing the parietal peritoneum, and pulling back the needle 0.5 cm, the area of the thin transversus abdominis muscle fibers wiil be infiltrated. In this area, the correct plane of the needle tip will confirm by observing Doyle's bulge and the spread of the local anesthetic.
Study: NCT04534140

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HBKB Capsule
Description: The botanical dietary supplement 'Halo Beauty Kiwi Booster' (HBKB) taken daily orally.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: HBKB Supplement Vehicle
Description: Control group participants will take one capsule of the HBKB botanical dietary supplement vehicle orally, once daily
Study: NCT06520683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: - Tislelizumab 200mg (day 1 and day 22), administered after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant chemotherapy
Description: * Adjuvant therapy is not mandatory.~* Optional adjuvant regimens include FOLFOX, CapeOX, 5-FU+LV, or Capecitabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Description: * Adjuvant therapy is not mandatory.~* Optional adjuvant regimens include FOLFOX, CapeOX, 5-FU+LV, or Capecitabine.
Study: NCT06385158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS1-144 tablet
Description: GS1-144 tablet is an NK3R antagonist.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GS1-144 tablet
Description: GS1-144 tablet is an NK3R antagonist.
Study: NCT06345846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IFIOL
Description: Implanted IFIOL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SFIOL
Description: Implanted SFIOL
Study: NCT05929651

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACYW conjugate vaccine
Description: Pharmaceutical form: Liquid solution Route of administration: Intramuscular (IM) injection